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Standards in prophylaxis: Prevention of
invasive aspergillosis in patients with
hematologic malignancies
D. Kontoyiannis
University of Texas, Houston, USA
Best practice strategies regarding primary antifungal prophy-
laxis in leukemiapatients and inhematopoietic stemcell transplant
recipients continue to evolve. For this prophylaxis to be beneﬁ-
cial and cost-effective, the risk of a life-threatening invasive fungal
infection (IFI) should outweigh the risks of toxic effects and drug
interactions introduced by the antifungal agent used. Furthermore,
the improved survival of such patients with IFIs creates pressing
issues regarding optimization of secondary antifungal prophy-
laxis. Not all patients with hematologic cancer recipients have the
same risk of IFIs. Well tolerated and pharmacokinetically reliable,
broad-spectrum antifungals, especially azoles, have the potential
for reducing IFI-associated mortality in these patients. Further
reﬁnement of risk stratiﬁcation and risk/beneﬁt analysis (includ-
ing pharmacoeconomic analysis) is needed. Stratiﬁcation of IFI risk
could be further sharpened based on emerging genetic, metabolic
risk factors. Despite robust data from randomized prospective
studies, personalized decisions and reliance on institution-speciﬁc
epidemiologic data are still expected to be a major part of “art and
science” of prophylaxis for fungal infections in severely immuno-
suppressed hosts.
http://dx.doi.org/10.1016/j.ijid.2014.03.498
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Implication of current resistance trends on
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As the prevalence of antibiotic-resistant Streptococcus pneumo-
niae, includingmultidrug-resistant strains is variableworld-wide1,
ﬁrst-line therapy with beta-lactams, macrolides, and increasingly
quinolones, in some regions has become limited in the treatment
of respiratory tract infections (RTIs). Therefore, one of the impor-
tant principles for appropriate antibiotic prescribing and effective
outcomes in this clinical setting is to recognise local resistance
prevalence.2 The aim of surveillance is both to guide empirical
antibiotic use and to improve the quality of empirical antimicro-
bial treatment in the community (as well as the hospital setting).3
In addition, introduction of pneumococcal vaccines may alter the
predominant serotypes with potentially unique antimicrobial sus-
ceptibility patterns.
There have been a number of international surveillance sys-
tems established including the ALEXANDER PROJECT, PROTEKT,
LIBRA, SENTRY, ANSORP4 and SIREVA.5 Survey Of Antibiotic Resis-
tance (SOAR)6 is the latest of the international surveillance studies
that offer standardised, internationally recognised methods that
provide quantitative data (minimum inhibitory concentrations
[MIC]) that may show slight shifts in resistance - as seen in pub-
lished SOAR data.6 These ‘shifts’ in antibioticMICs can be overcome
by extending the time above MIC (T >MIC) for which amoxicillin,
for example, is present in serum.7
In addition to MIC shifts, an increase in the prevalence of
Haemophilus inﬂuenzaehasbeenobserved inupperRTIs subsequent
towide-scale use of pneumococcal conjugate vaccines in children.8
This phenomenon, as well as an increase in beta-lactamase pro-
duction amongst H.inﬂuenzae in certain parts of the world, has
necessitated the ﬁrst line empirical use of amoxiciilin-clavulanate
as opposed to amoxicillin alone.9 Continuous surveillance through
standardised systems is therefore crucial to guide clinicians in
rational antibiotic prescribing for community acquired RTIs.
http://dx.doi.org/10.1016/j.ijid.2014.03.499
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Judicious use of antibiotics is promoted largely because of the
threat of antibiotic-resistant pathogens. The most common rea-
sons for antibiotic prescriptions in all ages are respiratory tract
infections (RTIs). The most common patients to receive antibiotics
are infants and young children, and among these, the commonest
diagnosis for which antibiotics are prescribed is otitis media.
Antibiotic resistance in the community is spread through selec-
tion of antibiotic-resistant respiratory ﬂora submitted to antibiotic
pressure during treatment of various acute diseases. Not all antibi-
otics are equal in their effect on promotion of antibiotic resistant
organisms. Using the pneumococcus paradigm, azithromycin is
the antibiotic with the highest promotion of resistance, due to
its long half life and low extra-cellular concentration; followed by
oral cephalosporins. Traditionally, “judicious use of antibiotics” is
translated by most clinicians as “reducing antibiotic use”. How-
ever judicious use means much more than that. There is a need
to consider all the following to successfully execute a judicious use
of antibiotics (as summarized by Ball et al, Journal of Antimicrobial
Chemotherapy 2002;49:31-40): 1) Treatment of bacterial infections
only; 2) optimize treatment by diagnosis and severity assessment;
3) maximize bacterial eradication; 4) recognize local resistance
prevalence; 5) utilize pharmacokinetics/pharmacodynamics for
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effective agents and dosage; and 6) integrate local resistance,
efﬁcacy and cost effectiveness. Judicious use is of utmost impor-
tance to assure retention of antibiotic susceptibility of respiratory
pathogens.
http://dx.doi.org/10.1016/j.ijid.2014.03.500
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Does guideline adherence have a positive
impact on the outcome of community-acquired
respiratory tract infection?
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Community-acquired respiratory tract infections (CA-RTIs) are
a common reason for the presentation of patients for medical care,
duringwhichanantibiotic is commonlyprescribed, and these infec-
tions are associated with considerable morbidity and/or mortality.
Clinical practice guidelines have been developed in many parts of
the world, with the aim of improving the overall quality of care
in order to achieve the best patient outcomes. However, despite
reviewing similar evidence, there arediscrepancies in the antibiotic
recommendations of guidelines from different parts of the world,
which may relate either to differences in the interpretation of the
same evidence base, or to local differences in the epidemiological
aspects of the various infections. Importantly, in order to ensure
that the guidelines are effective, there is a need to evaluate the lev-
els of adherence to the speciﬁc guideline recommendations, aswell
as to determine whether guideline adherence is associated with
improved patient outcomes. In general, studies have clearly doc-
umented that there are relatively poor levels of adherence to the
antibiotic recommendations of the various guidelines. In the case of
upper respiratory tract infections (URTIs), there tends to be overuse
of antibiotics, in general, with the prescription of a much broader
spectrum of agents than is commonly required. Furthermore, since
the overall beneﬁt of antibiotics in URTIs is relatively small, it is
usually difﬁcult to document an improvement in patient outcomes
with antibiotic adherence. The evidence in the case of lower respi-
ratory tract infections is much more clear-cut. While generally the
levels of adherence to the antibiotic recommendations also tend
to be rather low, there is evidence in sicker patients, such as those
with severe exacerbations of chronic obstructive pulmonary dis-
ease and in cases with community-acquired pneumonia, including
the elderly and critically ill patients, that adherence to the guideline
recommendations is clearly associated with improved outcomes.
Among these beneﬁts is improved patient survival, shorter times
to clinical stability, time to switch therapy, and length of hospital
stay, and also evidence of improved cost effectiveness of care. All
these issues will be addressed in the current presentation.
http://dx.doi.org/10.1016/j.ijid.2014.03.501
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Schistosomiasis
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Although still largely neglected and underappreciated, schisto-
somiasis is an important infectiousdiseaseof poverty. Indeed, some
800 million people are at risk of schistosomiasis and more than
200 million people are infected with blood-dwelling trematodes
of the genus Schistosoma. In 2010, the global burden of schisto-
somiasis has been estimated at 3.3 million disability-adjusted life
years, and this burden was largely concentrated on sub-Saharan
Africa. Perhaps more than any other infectious disease, schisto-
somiasis is deeply rooted in social-ecological systems and the
disease is common where poverty persists. Transmission occurs
through human-water contact patterns; hence, is governed by
social behaviour (e.g. open defecation that contaminates unpro-
tected freshwater bodies) and ecological factors (e.g. living in close
proximity to suitable freshwater bodies inhabited by intermedi-
ate host snails). The current mainstay of schistosomiasis control –
endorsed by the World Health Assembly in 2001 and reinforced
by the London Declaration in 2012 – is preventive chemotherapy.
This strategy emphasises the periodic, large-scale administra-
tion of the antischistosomal drug praziquantel to school-aged
children and other high-risk groups. While preventive chemother-
apy is the backbone of morbidity control, it fails to address the
root behavioural, ecological and social causes of schistosomiasis.
Hence, additional tools and strategies are required that should be
combined with preventive chemotherapy, readily tailored to spe-
ciﬁc social-ecological contexts and adapted over time. There is a
considerable body of historic evidence with multi-sectoral, inte-
grated intervention packages that interrupted the transmission of
schistosomiasis and achieved local elimination. Importantly, con-
temporary experiences document the impact of such integrated
control packages beyond the target disease schistosomiasis, thus
tackling other infectious diseases of poverty.
http://dx.doi.org/10.1016/j.ijid.2014.03.502
